““Point blank, these are Coke and Pepsi in lung cancer, OK?” Bristol-Myers Chief Scientific Officer Thomas Lynch told a hotel ballroom packed with analysts and investors at a major medical conference in Chicago. Merck & Co.’s drug, Keytruda, had shown impressive results at the conference -- but Bristol-Myers was right there with it, Lynch said. The analogy fell flat with an analyst at Sanford C. Bernstein & Co., Tim Anderson, who later pointed out that Coke commands about double the market share of Pepsi, just as Merck now appears to have a strong lead over Bristol-Myers in selling the drugs.“